Top 20 brands, latest PBS roundup


Pharma in Focus
 & Mercurial reports on some interesting trends among the top 20 PBS products for the quarter of September 30. Figures released by the PBS show that Humira’s (adalimumab) dominance continues, while Eylea (afibercept) and Lucentis (ranibizumab) are neck and neck in second and third spot respectively. For more on this article click here.

 

Analytics for this pharma in focus story was generated using MiPortal, Mercurial’s cloud-based business intelligence & analytics platform. Click here for a free trial or contact Regan McCracken – Director – Commercial Effectiveness, on 02 8705 8754.

Top 20 Leading BrandsAbout Pharma in Focus

Pharma in Focus (PIF) is Australia’s premier independent pharma industry news service.

PIF deliver up-to-date, in-depth news coverage, analysis and opinion straight to your desktop each working day of the week, covering the whole pharma sector, both prescription and non-prescription in Australia and New Zealand.